Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

If the 35% fall in Paytm&nbsp;was not enough, Macquarie believes the pain is not over for the fintech. The brokerage initiating coverage with an Underperform rating expects Paytm&nbsp;stock to fall all the way to their target of Rs 1200/share vs it's issue price of Rs 2150, implying a 45% fall.&nbsp;Here is Macquaire's&nbsp;take on Paytm-:

We believe PayTM&rsquo;s business model lacks focus and direction.&nbsp;
Achieving scale with profitability a big challenge; company is a cash guzzler&nbsp;
Unless PayTM lends, it can&rsquo;t make significant money by merely being a distributor&nbsp;
Obtaining a small finance bank license could be difficult in our view given that Chinese controlled firms own more than a 30% stake in PayTM.&nbsp;
Not enthused with the company&rsquo;s complicated organisation structure, related-party transactions, churn in top management and a thinly staffed board with 75% of members being based out of India.

Paytm&nbsp;marketcap has eroded over Rs 50,000 cr in just two sessions of trade.&nbsp;

Paytm lacks focus and direction, expect more downside says Macquarie 

Macquaire expects more downside in Paytm says the business model lacks focus and direction.

Paytm's Pain, Macquarie says more downside ahead

Macquarie puts&nbsp;Paytm stock target at Rs 1200, 45% lower than issue price

If the 35% fall in Paytm&nbsp;was not enough, Macquarie believes the pain is not over for the fintech. The brokerage initiating coverage with an Underperform rating expects Paytm&nbsp;stock to fall all the way to their target of Rs 1200/share vs it's issue price of Rs 2150, implying a 45% fall.&nbsp; Here is Macquaire's&nbsp;take on Paytm-:
<ul>
<li>We believe PayTM&rsquo;s business model lacks focus and direction.&nbsp;</li>
<li>Achieving scale with profitability a big challenge; company is a cash guzzler&nbsp;</li>
<li>Unless PayTM lends, it can&rsquo;t make significant money by merely being a distributor&nbsp;</li>
<li>Obtaining a small finance bank license could be difficult in our view given that Chinese controlled firms own more than a 30% stake in PayTM.&nbsp;</li>
<li>Not enthused with the company&rsquo;s complicated organisation structure, related-party transactions, churn in top management and a thinly staffed board with 75% of members being based out of India.</li>
</ul>
Paytm&nbsp;marketcap has eroded over Rs 50,000 cr in just two sessions of trade.&nbsp;

Cadila Healthcare&nbsp;is buzzing in trade as&nbsp;Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world's first Plasmid DNA vaccine for Covid-19. Brokergaes&nbsp;from Morgan Stanley to CLSA&nbsp;are extremely bullish on the stock on the prospect of the vaccine&nbsp;CLSA&nbsp;on Cadila&nbsp;Health: Upgraded the stock to a buy with target of Rs 650/share which is a 20% upside from Friday's close. The brokerage expects a double digit growth from the core business and says the recent correction now offers a good entry point.&nbsp;Morgan Stanley on Cadila&nbsp;Health: Though Morgan is keeping an equal weight they have a more aggressive price target at Rs 664/share as they expect the vaccine launch will provide the pivot to the stock and expect large scale&nbsp;adoption of the dose.&nbsp;

Cadila gets the right dose! Brokerages bullish after Covid 19 vaccine nod, upgrades from CLSA & Morgan 

Cadila gets the right dose! Brokerages bullish after Covid 19 vaccine nod, upgrades from CLSA, Morgan Stanley.&nbsp;

The Zycov D bullish bet

Company expects to launch the vaccine in September, pricing not yet decided.&nbsp;

Cadila Healthcare&nbsp;is buzzing in trade as&nbsp;Zydus Cadila has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D, the world's first Plasmid DNA vaccine for Covid-19. Brokergaes&nbsp;from Morgan Stanley to CLSA&nbsp;are extremely bullish on the stock on the prospect of the vaccine&nbsp; CLSA&nbsp;on Cadila&nbsp;Health: Upgraded the stock to a buy with target of Rs 650/share which is a 20% upside from Friday's close. The brokerage expects a double digit growth from the core business and says the recent correction now offers a good entry point.&nbsp; Morgan Stanley on Cadila&nbsp;Health: Though Morgan is keeping an equal weight they have a more aggressive price target at Rs 664/share as they expect the vaccine launch will provide the pivot to the stock and expect large scale&nbsp;adoption of the dose.&nbsp;

Brokerages are betting big on Phoenix Mills as debt overhang eases with stake divestment in key assets.&nbsp;What has changed for Phoenix Mills?
The company has signed a deal to divest a 26.44% stake to GIC in five operational assets for Rs 1100 cr.&nbsp;GIC may infuse an additional Rs 4000 cr and increase its stake to 33%-36% within 12 months.CLSA&nbsp;ugrades the stock to a BUYPhoenix mill remains one of the best Covid-19 recovery plays&nbsp; as per CLSA&nbsp;and they&nbsp;lift the target price from Rs 855 to Rs970 mainly due to the value accretion from the GIC deal. The brokerage also&nbsp;upgraded the rating from Outperform to BUY on the stock

Brokerage Bets: BUY Phoenix MIlls

Buzzing Stock: Brokerages bet on Phoenix Mills, CLSA upgrades to BUY

Brokerages are betting big on Phoenix Mills as debt overhang eases with stake divestment in key assets.&nbsp; What has changed for Phoenix Mills?
The company has signed a deal to divest a 26.44% stake to GIC in five operational assets for Rs 1100 cr.&nbsp;GIC may infuse an additional Rs 4000 cr and increase its stake to 33%-36% within 12 months. CLSA&nbsp;upgrades the stock to a BUY Phoenix mill remains one of the best Covid-19 recovery plays&nbsp; as per CLSA&nbsp;and they&nbsp;lift the target price from Rs 855 to Rs970 mainly due to the value accretion from the GIC deal. The brokerage also&nbsp;upgraded the rating from Outperform to BUY on the stock

Here are the top stocks on the brokerages radar-:
CLSA on Aurobindo Pharma

Cuts rating from BUY to Outperform on limited upside
Sets price target at Rs 1040/share (+4% upside)
Limited upside following the recent rally leading to cut in rating

Morgan Stanley on Glenmark Pharma

Raises price target to Rs 554/sh vs Rs 424/share earlier
Expect 8-10 launches (including three niche products) in the US
Retain Underweight rating on the stock&nbsp;

ICICI Sec on PNB Housing Finance&nbsp;

Upgrade to BUY&nbsp;rating
Raise price target to Rs 678/sh vs Rs 385/sh earlier&nbsp;
Board approval for preferential issue to Carlyle reduces overhang
Aditya Puri&rsquo;s nomination to the Board will lend considerable credence

Kotak&nbsp;Instl&nbsp;Equities on Karur Vysya Bank&nbsp;

Maintain Buy rating,&nbsp; Price target at Rs 65/sh
Decline in operating profits on account of lower provisions
Asset quality is showing resilience


Brokerage Bets for Tuesday's Trade: PNB Housing, Glenmark, Aurobindo Pharma

Brokerage Bets for Tuesday's Trade, stocks you need to keep an eye on

Brokerage Bets 

Here are the top stocks on the brokerages radar-:
CLSA on Aurobindo Pharma
<ul>
<li>Cuts rating from BUY to Outperform on limited upside</li>
<li>Sets price target at Rs 1040/share (+4% upside)</li>
<li>Limited upside following the recent rally leading to cut in rating</li>
</ul>
Morgan Stanley on Glenmark Pharma
<ul>
<li>Raises price target to Rs 554/sh vs Rs 424/share earlier</li>
<li>Expect 8-10 launches (including three niche products) in the US</li>
<li>Retain Underweight rating on the stock&nbsp;</li>
</ul>
ICICI Sec on PNB Housing Finance&nbsp;
<ul>
<li>Upgrade to BUY&nbsp;rating</li>
<li>Raise price target to Rs 678/sh vs Rs 385/sh earlier&nbsp;</li>
<li>Board approval for preferential issue to Carlyle reduces overhang</li>
<li>Aditya Puri&rsquo;s nomination to the Board will lend considerable credence</li>
</ul>
Kotak&nbsp;Instl&nbsp;Equities on Karur Vysya Bank&nbsp;
<ul>
<li>Maintain Buy rating,&nbsp; Price target at Rs 65/sh</li>
<li>Decline in operating profits on account of lower provisions</li>
<li>Asset quality is showing resilience</li>
</ul>

Despite an unexpected loss in the quarter gone by brokerages continue to be bullish on Bank of Baroda citing asset quality improvement.&nbsp;CLSA&nbsp;while maintaining their BUY call on the stock have&nbsp;increased the price&nbsp;target price on the stock Rs 130 while raising earnings estimates by 4%-5%. The chinese&nbsp;brokerage expects BoB&nbsp;to have turned the corner as the slippage number comes in much below expectations.&nbsp;JPMorgan as well citing the low slippage numbers at Rs 3000 cr maintains Overweight stance on BoB&nbsp;but keeps a modest target of Rs 110 on the stock.&nbsp;Morgan Stanley though retains an Equal-Weight on the stock and is upbeat on the FY'22 outlook recommends its clients to look at a more modest price target of Rs 100/share.&nbsp;

Stock Bets: Brokerages bullish on Bank of Baroda see 50% upside 

Stock Bets: Brokerages bullish on Bank of Baroda see 50% upside in te stock

Stock Bets: Brokerages bullish on Bank of Baroda

Despite an unexpected loss in the quarter gone by brokerages continue to be bullish on Bank of Baroda citing asset quality improvement.&nbsp; CLSA&nbsp;while maintaining their BUY call on the stock have&nbsp;increased the price&nbsp;target price on the stock Rs 130 while raising earnings estimates by 4%-5%. The chinese&nbsp;brokerage expects BoB&nbsp;to have turned the corner as the slippage number comes in much below expectations.&nbsp; JPMorgan as well citing the low slippage numbers at Rs 3000 cr maintains Overweight stance on BoB&nbsp;but keeps a modest target of Rs 110 on the stock.&nbsp; Morgan Stanley though retains an Equal-Weight on the stock and is upbeat on the FY'22 outlook recommends its clients to look at a more modest price target of Rs 100/share.&nbsp;

brokerage bets

Categories